Increasing Prevalence of Chronic Blood Disorders to Foster the Growth of the Post Polycythemia Vera Myelofibrosis (PPV MF) Market

Published: Apr 2022

The global post polycythemia vera myelofibrosis (PPV MF) market is anticipated to grow at a considerable CAGR of 9.1% during the forecast period (2022-2028). The increasing prevalence of chronic blood disorders is acting as the prime factor impacting the growth. As per the information provided by the Centers for Disease Control and Prevention in 2019, sickle cell disease is a blood disorder that affects more than 100,000 people in the US. Furthermore, next-generation sequencing (NGS) has identified multiple somatic mutations in MPNs and has contributed substantially to our understanding of disease pathogenesis, highlighting the role of clonal evolution in disease progression. Moreover, disease prognostication has expanded from encompassing only clinical decision-making to including genomics in prognostic scoring systems. Thus, these are the above factors mentioned which will further drive the PPV MF market.

Browse the full report description of “Global Post Polycythemia Vera Myelofibrosis (PPV MF) Market Size, Share, and Trends Analysis Report By Type (Durvalumab, Givinostat, Glasdegib, Idelalisib, IMG-7289, and Others), By Application (Hospital, Clinic, and Others), Forecast 2022-2028” at https://www.omrglobal.com/industry-reports/post-polycythemia-vera-myelofibrosis-ppv-mf-market

However, a side effect from durvalumab is expected to hamper the growth of the market. Such Side effects are, bladder pain, bloating or swelling of the face, arms, hands, lower legs, or feet, bloody or cloudy urine, depressed mood, difficulty during urination, dry skin and hair, feeling cold, difficulty having a bowel movement, and others.

Market Coverage

The market number available for – 2021-2028

Base year- 2021

Forecast period- 2022-2028

Segment Covered- 

o By Type

o By Application

Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape- including Abbvie Inc., Celgene Corp., CTI BioPharma Corp., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., and Others.

Key questions addressed by the report

What is the market growth rate?

Which segment and region dominate the market in the base year?

Which segment and region will project the fastest growth in the market?

How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

Who is the leader in the market?

How are players addressing challenges to sustain growth?

Where is the investment opportunity?

Global Post Polycythemia Vera Myelofibrosis (PPV MF) Market Report Segment

By Type

  • Durvalumab
  • Givinostat
  • Glasdegib
  • Idelalisib
  • IMG-7289
  • Others

By Application

  • Hospital
  • Clinic
  • Others

Global Post Polycythemia Vera Myelofibrosis (PPV MF) Market Report Segment by Region

North America

United States

Canada

Europe

UK

Germany

Italy

Spain

France

Rest of Europe 

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific 

Rest of the World

Latin America 

Middle East & Africa

To learn more about this report request a free sample copy @https://www.omrglobal.com/request-sample/post-polycythemia-vera-myelofibrosis-ppv-mf-market